

# ZIMMER BIOMET HOLDINGS INC

ISIN: US98956P1021 WKN: 98956P102 Asset Class: **Stock**

|  |  |
|--|--|
| <b>Company</b>   | 2024/05/03 19:02:16  |
|  ZIMMER BIOMET | <b>Price</b><br><b>121.07</b><br>USD                               |
|  | <b>Difference</b> <span style="color: green;">▲</span> 2.20%(2.61) |



|                             |  |
|-----------------------------|--|
| <b>Contact Details</b>      |  |
| ZIMMER BIOMET HOLDINGS INC. | Tel: +1-574-373-3333   |
| - -                         | Fax: +   |
| 345 East Main Street        | Web: <a href="http://www.zimmerbiomet.com">http://www.zimmerbiomet.com</a>         |
| 46580 Warsaw                | E-mail: <a href="mailto:contactus@zimmerbiomet.com">contactus@zimmerbiomet.com</a> |

## Company Profile

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 4,609,500,000  |                        | 4,427,300,000  |                        | 4,885,000,000  |                        |
| <b>Common stock capital</b>           |                | 3,200,000              |                | 3,100,000              |                | 3,100,000              |
| <b>Fixed assets</b>                   | 16,887,400,000 |                        | 16,638,700,000 |                        | 18,571,400,000 |                        |
| <b>Equity capital of a company</b>    |                | 12,488,200,000         |                | 12,027,000,000         |                | 12,666,400,000         |
| <b>Cash and cash equivalents</b>      | 415,800,000    |                        | 375,700,000    |                        | 478,500,000    |                        |
| <b>Accrued liabilities</b>            |                | 0                      |                | 0                      |                | 0                      |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 2,857,400,000          |                | 2,358,200,000          |                | 3,467,900,000          |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 6,151,300,000          |                | 6,680,800,000          |                | 7,322,100,000          |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 751,400,000            |                | 886,500,000            |                | 972,600,000            |
| <b>Total assets</b>                   | 21,496,900,000 | 21,496,900,000         | 21,066,000,000 | 21,066,000,000         | 23,456,400,000 | 23,456,400,000         |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 18,000  | 18,000  | 19,500  |
| <b>Equity ratio</b>        | 58.13%  | 57.12%  | 54.02%  |
| <b>Debt-equity ratio</b>   | 72.03%  | 75.06%  | 85.10%  |

## Others

|                         | 2023  | 2022   | 2021  |
|-------------------------|-------|--------|-------|
| <b>Tax Expense Rate</b> | 3.95% | 27.83% | 3.90% |

# ZIMMER BIOMET HOLDINGS INC

ISIN: US98956P1021 WKN: 98956P102 Asset Class: **Stock**

## Income statement

|  | 2023          | 2022          | 2021          |
|--|---------------|---------------|---------------|
| <b>Turnover</b>  | 7,394,200,000 | 6,939,900,000 | 7,836,200,000 |
| <b>Net income</b>  | 1,024,000,000 | 290,200,000   | 401,600,000   |
| <b>EBIT</b>  | 1,183,813,760 | 532,181,760   | 587,125,120   |
| <b>Operating income before taxes</b>                                 | 1,067,300,000 | 403,500,000   | 418,400,000   |
| <b>Cash Flow</b>   | 1,581,600,000 | 1,284,700,000 | 1,499,200,000 |
| <b>Net interest income</b>   | -195,300,000  | -164,100,000  | -207,800,000  |
| <b>Research and development expenses</b>                             | 458,700,000   | 406,000,000   | 497,200,000   |
| <b>Income taxes</b>  | 42,200,000    | 112,300,000   | 16,300,000    |
| <b>Result from investments in subsidiaries, associates and other</b> | 0             | 0             | 0             |
| <b>Revenues per employee</b>   | 385,156       | 361,492       | 376,781       |

## Board of Directors

## Members of Management Board

|                     |                                |
|---------------------|--------------------------------|
| Christopher Begley  | Chairman of Board of Directors |
| Arthur Higgins      | Member of Board of Directors   |
| Betsy Bernard       | Member of Board of Directors   |
| Louis Shapiro       | Member of Board of Directors   |
| Maria Hilado        | Member of Board of Directors   |
| Michael Farrell     | Member of Board of Directors   |
| Michael Michelson   | Member of Board of Directors   |
| Robert Hagemann     | Member of Board of Directors   |
| Sreelakshmi Kolli   | Member of Board of Directors   |
| Syed Jafry          | Member of Board of Directors   |
| Ivan Tornos         | Chairman of Managing Board     |
| Angela Main         | Member of Executive Committee  |
| David J. Kunz       | Member of Executive Committee  |
| Kenneth R. Tripp    | Member of Executive Committee  |
| Keri P. Mattox      | Member of Executive Committee  |
| Lori Winkler        | Member of Executive Committee  |
| Rachel H. Ellingson | Member of Executive Committee  |
| Sang Yi             | Member of Executive Committee  |
| Suketu Upadhyay     | Member of Executive Committee  |
| Wilfred van Zuilen  | Member of Executive Committee  |
| Zeeshan Tariq       | Member of Executive Committee  |